Drug · DIN 02497247
CABENUVA
KIT CONTAINING: A) VIAL (2 ML CABOTEGRAVIR) AND B) VIAL (2 ML RILPIVIRINE)
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 21, 2020; first marketed September 21, 2020.
- Drug Identification Number (DIN)
- 02497247
- Company (DIN owner)
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Kit; Suspension (Extended-Release)
- Route
- Intramuscular
- Therapeutic class (ATC)
- Antivirals for treatment of HIV infections, combinations J05AR
- Class
- Human
- Record last updated
- September 21, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| CABOTEGRAVIR | 200 MG | ML |
| RILPIVIRINE | 300 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 18, 2020: NOC 23362New Drug Submission (NDS)
Other DINs named CABENUVA
- DIN 02497220 · Marketed